Addressing COVID-19 vaccine hesitancy in rural community pharmacies: a protocol for a stepped wedge randomized clinical trial.
Addressing COVID-19 vaccine hesitancy in rural community pharmacies: a protocol for a stepped wedge randomized clinical trial.
复制标题
DOI：
10.1186/s13012-023-01327-7
复制
发表时间：
2023-12-18
影响因子：
7.2
通讯作者：
Carpenter, Delesha
中科院分区：
文献类型：
--
作者：
Curran, Geoffrey;Mosley, Cynthia;Gamble, Abigail;Painter, Jacob;Ounpraseuth, Songthip;Brewer, Noel T.;Teeter, Ben;Smith, Megan;Halladay, Jacquie;Hughes, Tamera;Shepherd, J. Greene;Hastings, Tessa;Simpson, Kit;Carpenter, Delesha
关键词：
在美国，COVID-19疫苗的接种率仍然很低，特别是在农村地区。COVID-19疫苗的犹豫与较低的接种率有关，这意味着在疫苗接种覆盖率较低的社区对SARS-CoV-2变体的易感性较高。由于社区药剂师是农村地区最容易获得和最值得信赖的卫生专业人员之一，因此这项随机临床试验将研究实施策略，以支持农村药剂师提供适应性循证干预措施，以减少COVID-19疫苗的犹豫。我们将采用不完全的阶梯楔形试验设计，随机抽取30家农村药店（分析单位），以确定标准实施办法的有效性和增量成本效益（包括描述疫苗犹豫干预的在线培训，现场网络研讨会，和资源网站）相比，（由经过培训的协调员提供，以支持药剂师提供疫苗犹豫咨询干预）。该干预措施（ASORT）是通过与美国南部七个州基于实践的研究网络中的农村药房合作，从HPV疫苗的循证疫苗传播干预措施中改编而来的。ASORT教授药剂师如何识别符合COVID-19疫苗接种条件的人（包括加强剂），以非对抗性的方式征求和解决疫苗问题，推荐疫苗，并在需要时重复这些步骤。主要的试验结果是对ASORT干预的忠诚度，这将通过对药剂师提供干预的记录进行评级来确定。次要结果是干预的有效性，由接受干预后同意接种疫苗的患者比例决定。其他次要结果包括可行性、可接受性、采用率、覆盖范围和成本。将进行成本效益和预算影响分析，以最大限度地发挥今后传播和可持续性的潜力。混合方法将提供三角测量、扩展和定量结果的解释。这项试验有助于增加疫苗犹豫干预措施的证据基础，并促进社区卫生环境中基于证据的实践。该试验将提供对药房环境中不同实施策略的相对价值的首次估计。NCT 05926544（clinicaltrials.gov）; 2023年3月7日。
Uptake of COVID-19 vaccines remains problematically low in the USA, especially in rural areas. COVID-19 vaccine hesitancy is associated with lower uptake, which translates to higher susceptibility to SARS-CoV-2 variants in communities where vaccination coverage is low. Because community pharmacists are among the most accessible and trusted health professionals in rural areas, this randomized clinical trial will examine implementation strategies to support rural pharmacists in delivering an adapted evidence-based intervention to reduce COVID-19 vaccine hesitancy. We will use an incomplete stepped wedge trial design in which we will randomize 30 rural pharmacies (unit of analysis) to determine the effectiveness and incremental cost-effectiveness of a standard implementation approach (consisting of online training that describes the vaccine hesitancy intervention, live webinar, and resource website) compared to adding on a virtual facilitation approach (provided by a trained facilitator in support of the delivery of the vaccine hesitancy counseling intervention by pharmacists). The intervention (ASORT) has been adapted from an evidence-based vaccine communication intervention for HPV vaccines through a partnership with rural pharmacies in a practice-based research network in seven southern US states. ASORT teaches pharmacists how to identify persons eligible for COVID-19 vaccination (including a booster), solicit and address vaccine concerns in a non-confrontational way, recommend the vaccine, and repeat the steps later if needed. The primary trial outcome is fidelity to the ASORT intervention, which will be determined through ratings of recordings of pharmacists delivering the intervention. The secondary outcome is the effectiveness of the intervention, determined by rates of patients who agree to be vaccinated after receiving the intervention. Other secondary outcomes include feasibility, acceptability, adoption, reach, and cost. Cost-effectiveness and budget impact analyses will be conducted to maximize the potential for future dissemination and sustainability. Mixed methods will provide triangulation, expansion, and explanation of quantitative findings. This trial contributes to a growing evidence base on vaccine hesitancy interventions and virtual-only facilitation of evidenced-based practices in community health settings. The trial will provide the first estimate of the relative value of different implementation strategies in pharmacy settings. NCT05926544 (clinicaltrials.gov); 07/03/2023.
登录
查看更多内容
DOI：
10.1186/1748-5908-4-50
发表时间：
2009-08-07
期刊：
Implementation science : IS
影响因子：
--
作者：
Damschroder LJ;Aron DC;Keith RE;Kirsh SR;Alexander JA;Lowery JC
通讯作者：
Lowery JC
影响因子：
13.8
作者：
Bauer, Mark S.;Miller, Christopher J.;Weaver, Kendra
通讯作者：
Weaver, Kendra
影响因子：
2.9
作者：
Berends, L;Johnston, J
通讯作者：
Johnston, J
影响因子：
25.4
作者：
Brewer, Noel T.;Chapman, Gretchen B.;Kempe, Allison
通讯作者：
Kempe, Allison
DOI：
10.1016/j.sapharm.2019.05.022
发表时间：
2020-03
期刊：
Research in social & administrative pharmacy : RSAP
影响因子：
--
作者：
Teeter BS;Mosley C;Thomas JL;Martin B;Jones D;Romero JR;Curran GM
通讯作者：
Curran GM